IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
IGC Pharma, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.24−0.00 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $24.28M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.1574 (−39.41%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
IGC Pharma, Inc. saw revenue fall 15.4% to $1.12M over the twelve months to Jun 30, 2026.
Revenue
$1.12M
-15.4% vs. a year earlier
Operating income
-$11.08M
TTM Q1 2027
EPS, diluted
-$0.08
TTM Q1 2027
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $24.28M
- P/E ratio
- –
- Price to sales
- 21.62
- Price to book
- 3.96
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.12M
- Net income
- -$7.89M
- EPS, diluted
- -$0.08
- Book value per share
- $0.06
- Diluted shares
- 100M
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
$1.12M-15.4% YoY
Gross profit
$246.00K-59.7% YoY
Operating income
-$11.08M
Net income
-$7.89M
EPS, diluted
-$0.08
Free cash flow
–
Reported periodTrailing twelve months